Table 1 Datasets and criteria for evaluating patients’ responses to immunotherapy for different cancer types
Data name | Cancer type | Therapeutic agent | Classified as “response” | Classified as “non-response” | Protocol |
|---|---|---|---|---|---|
GSE19423 | BLCA | BCG | responder(n = 43) | progressor(n = 5) | Cystoscopy and urinary cytology |
GSE111636 | BLCA | anti-PD-1(pembrolizumab) | responder(n = 6) | progressor(n = 5) | —— |
GSE67501 | RCC | anti-PD-1(nivolumab) | ‘CR’,‘PR’(n = 4) | ‘SD’, ‘NR’(n = 7) | RECISTa |
Miao D, et al.(aPD1) | KIRC | anti-PD-1(nivolumab) | ‘CR’,‘PR’(n = 3) | ‘SD’, ‘PD’(n = 13) | RECIST |
GSE100797 | SKCM | Adoptive T cell therapy | ‘CR’,‘PR’(n = 10) | ‘SD’, ‘PD’(n = 15) | RECIST |
GSE91061 | SKCM | anti-PD-1(nivolumab) or anti-CTLA-4 progression + anti-PD-1(nivolumab,ipilimumab) | ‘CR’,‘PR’(n = 10) | ‘SD’, ‘PD’(n = 39) | RECIST |
GSE91061 (aCTLA4 prog aPD1) | SKCM | anti-CTLA-4 progression + anti-PD-1(nivolumab,ipilimumab) | ‘CR’,‘PR’(n = 4) | ‘SD’, ‘PD’(n = 22) | RECIST |
GSE121810(NA-aPD1) | GBM | Neoadjuvant anti-PD-1 + adjuvant anti-PD-1(pembrolizumab) | —— | —— | —— |
GSE121810(A-aPD1) | GBM | Adjuvant anti-PD-1(pembrolizumab) | —— | —— | —— |